GLP-1s are game-changers if you've got significant weight to lose
December 18 Product: Xcoverys Ensacove Indication: ALK-positive locally advanced or metastatic non-small cell lung cancer Florida-based Xcovery Holdings on Thursday scored its first FDA approval with the regulatory greenlight for Ensacove (ensartinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are also positive for the anaplastic lymphoma kinase (ALK) fusion gene
Manual screening of grey literature resulted in an addition of 18 articles
To minimize these events, Sean Wharton, MD, director of the Wharton Medical Clinic in Toronto, and colleagues suggest the three Es: E ducation and explanation E scalation to an appropriate dose E ffective management of GI side effects. Patients should be counseled on means to decrease adverse event risk such as reducing meal size
Then, youll decrease to one injection per week or per month
I mean, Clavicular, it should be noted, is an influencer